VetStem Biopharma, Inc., Announced that their Landmark Peer-Reviewed Manuscript on Stem Cell Therapy of Canine Osteoarthritis has been Published
VetStem Biopharma, Inc., announced that a landmark peer-reviewed manuscript on stem cell therapy of canine osteoarthritis has been published. The placebo-controlled study of allogeneic adipose stem cell therapy in dogs with clinical arthritis is the large
VetStem Biopharma, Inc., announced that a landmark peer-reviewed manuscript on stem cell therapy of canine osteoarthritis has been published. The placebo-controlled study of allogeneic adipose stem cell therapy in dogs with clinical arthritis is the largest study of its kind to date in the veterinary literature.
This double-blinded, multi-site, placebo-controlled field efficacy study enrolled approximately 90 dogs with osteoarthritis. The dogs, who received a single intra-articular injection of stem cells demonstrated a statistically significant improvement in treatment versus placebo (p<0.05). The primary endpoint was treatment success based on the Client-Specific Outcome Measurement (CSOM) on day 60 as compared to day 0. Additionally, the veterinary assessment of pain showed a statistically significant improvement in the stem cell treated dogs compared to the controls. The final study report was submitted to the FDA and the peer-reviewed manuscript was published in Frontiers in Veterinary Science – Veterinary Regenerative Medicine in the September 16, 2016 issue. Titled “A Prospective, Randomized, Masked, and Placebo-Controlled Efficacy Study of Intraarticular Allogeneic Adipose Stem Cells for the Treatment of Osteoarthritis in Dogs,” this study evaluated VetStem’s novel allogeneic stem cell product in client-owned dogs in a formal FDA study. The nine independent investigators in this study are leaders in surgery and pain management and are co-authors on the peer-reviewed publication.
As the first company in the world to offer fat derived stem cell services for veterinary use, VetStem has rapidly developed the market, providing treatments to over 12,000 horses, dogs, cats and exotic species. “With this progress in demonstrating the feasibility of using donor-derived (allogeneic) stem cells in treating osteoarthritis, VetStem hopes to deliver an FDA-approved “off-the-shelf” stem cell product in 2018 in its mission to bring this novel therapy to practitioners in a cost-effective manner,” said Dr. Bob Harman, CEO and Founder of VetStem.
The study was financially supported by Aratana Therapeutics, VetStem’s US licensee and commercial partner. Aratana will launch the product upon approval by the FDA and provide marketing and sales to deliver this product to the US veterinary markets. Aratana has recently received FDA approval for three new canine products, demonstrating both commitment and expertise in the growing pet therapeutics market. VetStem is also in the process to get EMA approval for launch in the European markets.